Skip Nav Destination
Issues
1 October 2017
-
Cover Image
Cover Image
ABOUT THE COVER
Quantitative liquid chromatography/mass spectrometry (LC/MS) metabolomics in two BRAF mutant human melanoma xenograft models (WM266.4 and A375), were used to select the metabolites increased or decreased in tumor versus non-tumor bearing animals, whose changes were reversed by the MEK inhibitor RO4987655. Of these 21 metabolites identified preclinically in these models that were sensitive to MEK inhibition, 15 on-treatment changes were significantly correlated with objective responses in patients with advanced melanoma treated with RO4987655 and seven metabolite levels had pre-treatment predictive value. For more details see the article by Ang and colleagues (beginning on page 2315). - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice
Leeanna El-Houjeiri; Walid Saad; Berthe Hayar; Patrick Aouad; Nadim Tawil; Rana Abdel-Samad; Rita Hleihel; Maguy Hamie; Angelo Mancinelli; Claudio Pisano; Hiba El Hajj; Nadine Darwiche
A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Tamara B. Garcia; Jonathan C. Snedeker; Dmitry Baturin; Lori Gardner; Susan P. Fosmire; Chengjing Zhou; Craig T. Jordan; Sujatha Venkataraman; Rajeev Vibhakar; Christopher C. Porter
PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature
Evgeni Efimenko; Utpal P. Davé; Irina V. Lebedeva; Yao Shen; Maria J. Sanchez-Quintero; Daniel Diolaiti; Andrew Kung; Brian J. Lannutti; Jianchung Chen; Ronald Realubit; Zoya Niatsetskaya; Vadim Ten; Charles Karan; Xi Chen; Andrea Califano; Thomas G. Diacovo
Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules
Khalid Z. Masoodi; Yadong Xu; Javid A. Dar; Kurtis Eisermann; Laura E. Pascal; Erica Parrinello; Junkui Ai; Paul A. Johnston; Joel B. Nelson; Peter Wipf; Zhou Wang
Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Jaya Gautam; Jin-Mo Ku; Sushil Chandra Regmi; Hyunyoung Jeong; Ying Wang; Suhrid Banskota; Myo-Hyeon Park; Tae-gyu Nam; Byeong-Seon Jeong; Jung-Ae Kim
Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Gaël S. Roth; Zuzana Macek Jilkova; Ayca Zeybek Kuyucu; Keerthi Kurma; Séyédéh Tayébéh Ahmad Pour; Giovanni Abbadessa; Yi Yu; Benoit Busser; Patrice N. Marche; Vincent Leroy; Thomas Decaens
Large Molecule Therapeutics
Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3–Targeted Liposomes
Anirudh Sattiraju; Xiaobing Xiong; Darpan N. Pandya; Thaddeus J. Wadas; Ang Xuan; Yao Sun; Youngkyoo Jung; Kiran Kumar Solingapuram Sai; Jay F. Dorsey; King C. Li; Akiva Mintz
Author Choice
Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer
Reema Railkar; L. Spencer Krane; Q. Quentin Li; Thomas Sanford; Mohammad Rashid Siddiqui; Diana Haines; Srinivas Vourganti; Sam J. Brancato; Peter L. Choyke; Hisataka Kobayashi; Piyush K. Agarwal
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Josep Tabernero; Atsushi Ohtsu; Kei Muro; Eric Van Cutsem; Sang Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Jaffer A. Ajani; Jiri Tomasek; Howard Safran; Kumari Chandrawansa; Yanzhi Hsu; Michael Heathman; Azhar Khan; Lan Ni; Allen S. Melemed; Ling Gao; David Ferry; Charles S. Fuchs
Cancer Biology and Signal Transduction
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
Michael P. Sanderson; Marco H. Hofmann; Pilar Garin-Chesa; Norbert Schweifer; Andreas Wernitznig; Stefan Fischer; Astrid Jeschko; Reiner Meyer; Jürgen Moll; Thomas Pecina; Heribert Arnhof; Ulrike Weyer-Czernilofsky; Stephan K. Zahn; Günther R. Adolf; Norbert Kraut
Author Choice
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Kazuhiko Shien; Vassiliki A. Papadimitrakopoulou; Dennis Ruder; Carmen Behrens; Li Shen; Neda Kalhor; Juhee Song; J. Jack Lee; Jing Wang; Ximing Tang; Roy S. Herbst; Shinichi Toyooka; Luc Girard; John D. Minna; Jonathan M. Kurie; Ignacio I. Wistuba; Julie G. Izzo
The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Elisa Zanini; Louay S. Louis; Jane Antony; Evdoxia Karali; Imoh S. Okon; Arthur B. McKie; Sebastian Vaughan; Mona El-Bahrawy; Justin Stebbing; Chiara Recchi; Hani Gabra
Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression
Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K. Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E. Massey; Manish K. Tripathi; Fathi T. Halaweish; Nadeem Zafar; Man M. Singh; Murali M. Yallapu; Subhash C. Chauhan; Meena Jaggi
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
Kush Dalal; Meixia Che; Nanette S. Que; Aishwariya Sharma; Rendong Yang; Nada Lallous; Hendrik Borgmann; Deniz Ozistanbullu; Ronnie Tse; Fuqiang Ban; Huifang Li; Kevin J. Tam; Mani Roshan-Moniri; Eric LeBlanc; Martin E. Gleave; Daniel T. Gewirth; Scott M. Dehm; Artem Cherkasov; Paul S. Rennie
Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Louis-Bastien Weiswald; Mohammad R. Hasan; John C.T. Wong; Clarissa C. Pasiliao; Mahbuba Rahman; Jianhua Ren; Yaling Yin; Samuel Gusscott; Sophie Vacher; Andrew P. Weng; Hagen F. Kennecke; Ivan Bièche; David F. Schaeffer; Donald T. Yapp; Isabella T. Tai
Author Choice
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma
Salvia Jain; Abigail Washington; Rebecca Karp Leaf; Parul Bhargava; Rachael A. Clark; Thomas S. Kupper; Dina Stroopinsky; Athalia Pyzer; Leandra Cole; Myrna Nahas; Arie Apel; Jacalyn Rosenblatt; Jon Arnason; Donald Kufe; David Avigan
Companion Diagnostics and Cancer Biomarkers
Author Choice
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang; Akos Pal; Yasmin J. Asad; Alan T. Henley; Melanie Valenti; Gary Box; Alexis de haven Brandon; Victoria L. Revell; Debra J. Skene; Miro Venturi; Ruediger Rueger; Valerie Meresse; Suzanne A. Eccles; Johann S. de Bono; Stanley B. Kaye; Paul Workman; Udai Banerji; Florence I. Raynaud
Letter to the Editor
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds